CYTOPIA
Cytopia's mission is to develop targeted small molecule therapeutics for cancer. The company also aims to develop drugs for other diseases with unmet medical need including immune conditions, such as organ transplant rejection. Through its internal discovery and development expertise, Cytopia has devised a portfolio of drug candidates at various stages of formal development.
CYTOPIA
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2001-01-01
Address:
Richmond, Virginia, United States
Country:
United States
Website Url:
http://www.cytopia.com.au
Status:
Active
Contact:
61-3-9208-4222
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Facebook Sharer Gravatar Profiles
More informations about "Cytopia"
Cytopia - Crunchbase Company Profile & Funding
Cytopia's mission is to develop targeted small molecule therapeutics for cancer. The company also aims to develop drugs for other diseases with unmet …See details»
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN …
Oct 6, 2009 Cytopia's lead product, CYT997, has demonstrated potent disruption of existing tumor vasculature and therefore has the potential to synergize with existing marketed anti …See details»
YM BioSciences to Take Over Cytopia Gaining Base in Australia
Oct 6, 2009 Cytopia shareholders are being offered 0.0852 common shares of YM in exchange for each common share of Cytopia. This offer is based on the volume-weighted average price …See details»
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN
Oct 5, 2009 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of...See details»
YM BioSciences completes merger with Cytopia - Newswire
Feb 1, 2010 The products being developed by Cytopia, the JAK 1/2 inhibitor CYT387 and the novel VDA molecule CYT997 were discovered internally at Cytopia based on research led by …See details»
Cytopia - Overview, News & Similar companies | ZoomInfo.com
Cytopia's mission is to develop targeted small molecule therapeutics for cancer. The company also aims to develop drugs for other diseases with unmet medical need including immune …See details»
Cytopia Company Profile 2024: Valuation, Investors, Acquisition
When was Cytopia founded? Cytopia was founded in 1998. Where is Cytopia headquartered? Cytopia is headquartered in Richmond, Australia. What is the size of Cytopia? Cytopia has 50 …See details»
CYTOPIA PTY LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CYTOPIA PTY LIMITED of Melbourne, VICTORIA. Get the latest business insights from Dun & Bradstreet.See details»
YM BioSciences Announces $14.05 Million Offer for Cytopia
Oct 6, 2009 Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders. …See details»
Cytopia accepts takeover by Canadian biotech - The Sydney …
Oct 6, 2009 Cytopia option holders will receive YM options at an equivalent ratio. The agreed offer represents a share price offer of 16.59 cents per Cytopia share. It values the takeover …See details»
FDA approval for US$1.9B Australian-developed cancer …
Sep 19, 2023 Momelotinib was invented at Cytopia (ASX: CYT), an Australian biotech founded in 1999 by Professor Andrew Wilks, which was listed in 2004 (ASX: CYT). The Cytopia team was headed by Wilks and Dr Christopher …See details»
Cytopia to merge with YM BioSciences - The Sydney Morning Herald
Oct 6, 2009 Toronto based YM BioSciences Inc has made a $14.05 million recommended scrip offer for Australia's Cytopia Ltd, under which the pair will combine their respective cancer …See details»
Cytopia Ltd - Company Profile and News - Bloomberg Markets
Company profile page for Cytopia Ltd including stock price, company news, executives, board members, and contact informationSee details»
TIA-supported facility helps kick-start an Australian-developed …
Shortly after the establishment of the Centre for Drug Candidate Optimisation (CDCO) in the early 2000s, one of the centre’s first projects was to assist with the development of a series of …See details»
2024 Prime Minister’s Prize for Innovation | BioMelbourne Network
Oct 9, 2024 Cytopia’s Professor Andrew F Wilks and Dr Chris Burns received the 2024 Prime Minister’s Prize for Innovation. The prize recognises their outstanding contribution to drug …See details»
Australian-developed drug receives US FDA approval
Sep 19, 2023 The treatment was developed as candidate CYT387 at Cytopia, an Australian biotech company founded by Professor Andrew Wilks in 1999 and headed by Prof Wilks, Dr …See details»
Cytopia agrees to takeover - The Sydney Morning Herald
Oct 6, 2009 Cytopia option holders will receive YM options at an equivalent ratio. The agreed offer represents a share price offer of 16.59¢ per Cytopia share. It values the takeover offer at …See details»
Australian-developed blood cancer treatment approved by FDA
Sep 22, 2023 Momelotinib was originally invented at Cytopia, an Australian biotech founded in 1999 by Professor Andrew Wilks. The drug was the only asset of Sierra Oncology, which was …See details»
Cytopia inks major licensing deal with Novartis
Jun 4, 2006 Australia's Cytopia has signed one of the richest licensing deals recorded for that country. Novartis will pay Cytopia $13 million in up front fees and research funds over three …See details»
Cytopia announces novel anti-cancer drug development …
May 13, 2008 Cytopia Limited announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement …See details»